Core Insights - The "Top Ten Outstanding Figures in the Medical Aesthetics Industry for 2025" list was announced by Rui Finance, highlighting Guo Zhenyu, Chairman of Beitaini, as a notable figure in the industry [1][2] - The selection criteria for the list included professional ability, performance, and industry influence [1] Group 1: Company Overview - Guo Zhenyu, born in November 1963, holds Canadian nationality and has a five-year residency permit in China [2] - He has an extensive background in the pharmaceutical industry, having served as the chairman of various associations and organizations, including the World Self-Medication Industry Alliance and the China Non-Prescription Medicines Association [2] - Guo Zhenyu has been leading Beitaini since December 2016, focusing on research and development, product optimization, and market expansion [2] Group 2: Industry Position - Under Guo Zhenyu's leadership, Beitaini has achieved financial stability and long-term value growth in the sensitive skin care sector, solidifying its position as a market leader [2]

Overview - The report indicates a marginal improvement in the performance of public REITs in Q4 2025, with significant growth in public utility and consumer revenue, while industrial parks and warehousing have shifted from negative to positive growth. EBITDA declines in energy and transportation sectors have narrowed, and rental housing performance has faced slight pressure. The completion rates for distributable amounts of newly issued REITs for 2024 and 2025 are 79% and 64% respectively [2][13]. Consumer Sector - The consumer sector has shown strong performance during the peak season, with improvements in rental rates and occupancy across most projects. Two-thirds of the projects achieved their highest revenue in the last five periods, indicating overall strong performance [2][13]. Rental Housing - The overall occupancy rate in the rental housing sector remains high, but rental performance is mixed. Government-led projects have stabilized both volume and price, while market-driven projects have adjusted prices downward to maintain occupancy [2][13]. Public Utilities - The public utility sector has seen significant revenue growth due to an increase in waste sources for biomass projects. However, the heating supply in Jinan has underperformed expectations, and water-related projects have experienced seasonal declines [2][13]. Energy Sector - The energy sector is experiencing increased differentiation, with fluctuating power generation and generally declining electricity prices. Natural gas projects are under the most pressure, with EBITDA margins dropping to negative values, while offshore wind and photovoltaic projects remain stable [3][13]. IDC Sector - The IDC sector benefits from long-term contracts with major clients, leading to stable volume and price. The distribution amounts for IDC in Q4 2025 have seen significant growth [3][13]. Transportation Sector - Traffic volume in the transportation sector is influenced by changes in surrounding road networks. Some projects have benefited from traffic recovery due to completed construction, while others continue to face diversion pressures, leading to varied performance [3][13]. Warehousing and Logistics - The warehousing and logistics sector has seen a widening decline in rental rates for market-oriented leasing projects, but this has effectively driven an increase in occupancy rates. Overall, the industry is exhibiting a trend of "price for volume" [3][13]. Industrial Parks - The industrial park market is showing weak recovery and strong differentiation. Commercial office projects are facing significant rental pressure, while manufacturing parks have maintained stable revenue but experienced a general decline in EBITDA [3][13]. Cosmetics and Aesthetic Medicine Sector - The cosmetics sector is expected to see steady growth in brand performance, with retail sales of cosmetics projected to reach 4,653 billion yuan in 2025, a year-on-year increase of 5.1%, outperforming the overall retail market by 1.4 percentage points [14][16]. - Key players in the Hong Kong stock market, such as Up Beauty and Mao Ge Ping, are expected to report significant growth in GMV, driven by strong performance on platforms like Douyin during promotional events [14][16]. E-commerce and Agency Operations - The e-commerce agency sector is experiencing a resurgence, with companies like Yi Wan Yi Chuang and Shui Yang Co. expected to see substantial profit growth due to improved operational efficiency and brand development [16][16].

Investment Rating - The report rates the cosmetics and medical beauty industry as "Overweight" for 2025, indicating an expectation for the industry to outperform the overall market [2][11]. Core Insights - The demand side of the cosmetics and medical beauty sector is expected to accelerate, with retail sales of cosmetics projected to reach 465.3 billion yuan in 2025, a year-on-year growth of 5.1%, surpassing the overall retail growth by 1.4 percentage points [3]. - The performance of Hong Kong-listed beauty companies is strong, with significant growth in GMV (Gross Merchandise Volume) through platforms like Douyin, particularly during promotional events like Double Eleven [3]. - The A-share market shows a mixed performance, with companies like Ruoyuchen and Shanghai Jahwa experiencing substantial improvements in their earnings [3]. - The e-commerce operation sector is rebounding, with companies like Ruoyuchen and Yiwang Yichuang expected to see profit growth exceeding 50% in 2025 [3]. - The medical beauty segment is anticipated to face slight fatigue due to macroeconomic factors, but new product launches are expected to stimulate consumer interest in 2026 [3]. Summary by Sections Cosmetics Sector - Retail sales of cosmetics are projected to grow by 5.1% in 2025, with Q4 growth reaching 9.9% [3]. - Key companies such as Shiseido and Lin Qingxuan are expected to see significant GMV growth, with Lin Qingxuan projected to achieve triple-digit growth [3]. - Investment recommendations include companies with strong channel and brand matrices like Maogeping, Shiseido, and Lin Qingxuan, as well as those with improving earnings like Porlaia and Marubi [3]. Medical Beauty Sector - The medical beauty sector is expected to be impacted by macroeconomic conditions, with companies like Aimeike facing challenges [3]. - Recommendations focus on companies with strong R&D capabilities and broad product pipelines, such as Aimeike and Langzi [3]. E-commerce and Operations - The e-commerce operation sector is recovering, with companies like Ruoyuchen and Qingmu Technology expected to see significant profit growth [3]. - The report highlights the importance of self-operated brands and the potential for high growth in this segment [3]. Key Company Valuations - The report provides a valuation table for key companies, indicating a "Buy" rating for several firms including Porlaia, Maogeping, and Shiseido, with projected PE ratios reflecting growth expectations [5].

Market Overview - The medical beauty sector experienced a decline of 1.41% on January 27, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Aimei Ke (300896) closed at 140.31, down 1.20% with a trading volume of 31,300 shares and a transaction value of 439 million [1] - Jinbo Biological (920982) closed at 228.34, down 1.31% with a trading volume of 5,531 shares and a transaction value of 127 million [1] - Huaxi Biological (688363) closed at 46.43, down 1.59% with a trading volume of 49,700 shares and a transaction value of 229 million [1] - *ST Meigu (000615) closed at 3.19, down 2.15% with a trading volume of 108,900 shares and a transaction value of 34.8 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 41.32 million from main funds and a net outflow of 3.13 million from speculative funds, while retail investors had a net inflow of 44.45 million [1] - For *ST Meigu, the main funds had a net outflow of 9.71 million, accounting for -27.91% of the total, while retail investors had a net inflow of 7.40 million, representing 21.26% [2] - Huaxi Biological experienced a net outflow of 14.32 million from main funds, with a net inflow of 4.64 million from retail investors [2] - Aimei Ke had a net outflow of 17.28 million from main funds, with a net inflow of 32.41 million from retail investors [2] - Jinbo Biological saw a net outflow of 19.33 million from main funds, with a net outflow of 188,440 from retail investors [2]

Group 1 - The core viewpoint of the article is that the company, Aimeike (300896), is actively managing its market value through a share repurchase plan amounting to 399 million yuan (excluding transaction costs) in 2023 [1] - The company emphasizes its commitment to market value management and will disclose any specific plans in accordance with relevant laws and regulations [1]

Group 1 - The medical beauty sector experienced a slight decline of 0.03% on January 26, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the medical beauty sector showed mixed performance, with Huaxi Biological up 1.03% and *ST Meigu down 1.81% [1] Group 2 - The medical beauty sector saw a net outflow of 14.71 million yuan from main funds, while retail investors contributed a net inflow of 8.53 million yuan [1] - Detailed fund flow data indicates that Huaxi Biological had a main fund net inflow of 5.91 million yuan, while *ST Meigu experienced a significant main fund net outflow of 7.46 million yuan [2] - Retail investors showed a positive net inflow in several stocks, with Love Beauty seeing a retail net inflow of 26.41 million yuan despite a main fund outflow [2]

Core Insights - The 2025 public fund quarterly report indicates a "stronger getting stronger" trend in the active equity fund market, with performance and scale highly correlated to the technology sector and research capabilities [2][10] Group 1: Performance of Active Equity Funds - The median average return for active equity funds in 2025 was 38.30%, with the top ten managers achieving returns as high as 148.78% [2] - Allianz Fund was the only foreign-owned public fund company among the top ten managers, benefiting from deep investments in Chinese tech stocks [2][13] - BlackRock Fund faced challenges in China, with an average return of 27.79% for its ten active equity funds, ranking second to last among foreign-owned public funds [2][3] Group 2: Challenges Faced by BlackRock Fund - BlackRock Fund's core issue is a vague market positioning and lack of a clear "technology growth" brand, leading to underperformance in the 2025 structural bull market [3][7] - The fund's active equity products are seen as "trial" issues, lacking sustained marketing and investor education, resulting in a marginalization of these products [4][9] - Despite having a global research platform, BlackRock's local team has not established an independent active equity research system in China, leading to conservative product strategies [7][8] Group 3: Fund Structure and Holdings - BlackRock's active equity product line includes various fund types, but its active equity products have not seen new issues in 2025, indicating a lack of focus [4][7] - The fund's holdings are primarily concentrated in manufacturing, finance, and consumer sectors, with over 60% of the portfolio in these areas [7] - The flagship product, "BlackRock Advanced Manufacturing One-Year Holding A," led foreign peers with a 63.34% annual return, but other products underperformed [8][14] Group 4: Comparison with Other Foreign Funds - Other foreign public funds in China are transitioning from "trial" to "deep cultivation," showing significant differentiation in product layout, research systems, and performance [10][11] - Allianz Fund stands out with a focused market strategy, achieving a return of 96.01% for its only active equity product since its inception [13][14] - The overall trend indicates that foreign public funds are increasingly focusing on AI, high-end manufacturing, and semiconductor sectors, with a significant portion of their portfolios allocated to these areas [11][15]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating strong performance compared to the market [2]. Core Insights - The cosmetics and medical beauty sector has outperformed the market recently, with the Shenwan Beauty Care Index rising by 2.0% from January 16 to January 23, 2026, surpassing the Shenwan A Index by 0.8 percentage points [4][5]. - December 2025 saw a significant increase in social retail sales for cosmetics, reaching 38 billion yuan, with a growth rate of 8.8%, indicating robust demand even in the off-season. The overall growth rate for Q4 was 9.9%, significantly higher than the annual growth of 5.1% for 2025, driven by promotional events like Double 11 [10][17]. - The report anticipates continued high consumer demand in Q1 2026, supported by new product launches and regulatory approvals in the medical beauty sector [10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown strong performance, with the Shenwan Cosmetics Index increasing by 2.6% and the Shenwan Personal Care Index rising by 4.2%, both outperforming the Shenwan A Index [4][5]. Key Company Reviews - Lin Qingxuan (2657HK) is highlighted as a benchmark in the high-end domestic skincare market, with revenue projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a CAGR of 32.7%. The company is expected to turn a profit of 187 million yuan in 2024, a 120% increase year-on-year [11][12]. - Langzi Co., Ltd. (002612.SZ) forecasts a net profit of 900 million to 1.05 billion yuan for 2025, reflecting a year-on-year growth of 245.25% to 302.80% [4]. - Qingsong Co., Ltd. (300132.SZ) anticipates a net profit of 130 million to 165 million yuan for 2025, with a growth rate of 137.73% to 201.74% [4]. Market Trends - The report notes that the high-end skincare market is expanding, with the market size expected to reach 218.5 billion yuan by 2029. The concept of "oil-based skincare" is becoming mainstream, driving growth in the facial oil segment, which is projected to grow at a CAGR of 42.8% from 2019 to 2024 [12][14]. - E-commerce channels are increasingly important, with Lin Qingxuan achieving a 65.4% online revenue share in H1 2025, leveraging platforms like Douyin and Tmall for growth [13]. Sales Data - In December 2025, the total retail sales of cosmetics reached 38 billion yuan, with a year-on-year growth of 8.8%. The overall retail sales for cosmetics in 2025 were 465.3 billion yuan, reflecting a 5.1% increase [17][21].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The total retail sales in China for 2025 reached CNY 501,202 billion, with a year-on-year growth of +3.7%. December's retail sales showed a modest increase of +0.9% [25][34] - The retail sector is experiencing a gradual recovery, with service retail outperforming goods retail. Online sales are rebounding, while offline supermarkets, convenience stores, and specialty shops are performing relatively steadily [4][27] - The high-end traditional gold market is expanding, with brands like Laopu Gold gaining traction among high-net-worth consumers, supported by strong sales during promotional events [34][38] Summary by Sections Retail Sector Overview - The retail and social service indices reported increases of 2.16% and 3.20% respectively from January 19 to January 23, 2026, with the retail index ranking 16th among 31 sectors [6][15] - The jewelry sector has shown the highest growth, with an increase of 8.66% in the past week and 11.51% year-to-date [18][20] Consumer Trends - Essential consumer goods are stable, with food and oil products performing particularly well. In contrast, optional consumer goods show mixed results, with cosmetics and jewelry performing better than clothing and home appliances [31][33] - The online retail market for physical goods reached CNY 130,923 billion in 2025, growing by +5.2%, accounting for 26.1% of total retail sales [27][30] Investment Recommendations - Focus on high-quality companies in high-demand sectors driven by emotional consumption themes, particularly in gold and jewelry, with recommendations for brands like Laopu Gold, Chao Hong Ji, and Chow Tai Fook [7][41] - Emphasize offline retail companies adapting to market changes and AI-enabled cross-border e-commerce leaders, recommending companies like Yonghui Supermarket and Aiyingshi [7][39] - Highlight domestic beauty brands that innovate in emotional value and safety, recommending brands like Mao Ge Ping and Proya [7][39] - Consider differentiated medical beauty product manufacturers and expanding chain medical institutions, with recommendations for companies like Meili Tianyuan and Aimeike [7][39]

Group 1 - The company emphasizes the importance of investor relations and adheres to laws and regulations regarding information disclosure [1] - The company commits to providing timely and objective responses to investor suggestions and inquiries [1]